GLPwatch
Tirzepatide: A promising treatment for obesity?
JAAPA · 2023
Last updated 2026-05-28Tirzepatide is a new medication originally approved for type 2 diabetes that has shown promise for weight loss in people with obesity. In studies, it has helped participants lose significant amounts of weight, with one trial reporting an average loss of 15% of body weight over 72 weeks.
AI summary of the abstract below.
| Journal | JAAPA, 2023 |
|---|---|
| Citations | 0 |
| Relative citation ratio | 0.00 |
| NIH percentile | 0 |
| Molecules | tirzepatide |
| Conditions studied | Obesity |
Abstract
Obesity affects a large percentage of patients in the United States and is associated with increased mortality and higher healthcare costs. Newer guidelines recommend a minimum of 10% weight loss goal for patients with obesity, and medical management options fall short. Tirzepatide, the first available dual-incretin analog, is a novel treatment for type 2 diabetes that also can induce weight loss. This article discusses tirzepatide as a treatment for obesity.
Verbatim abstract via PubMed 37884034 ↗
Related research
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.